LX-4211 CAS 1018899-04-1

Khoom Piav Qhia:

Khoom Lub Npe: LX-4211 CAS TSIS TAU: 1018899-04-1

Lub ntsiab lus:

Sotagliflozin;

(2S, 3R, 4R, 5S, 6R) -2- [4-chloro-3- (4-ethoxy-benzyl) -phenyl] -6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol;

(2S, 3R, 4R, 5S, 6R) -2- (4-chloro-3- (4-ethoxybenzyl) phenyl) -6- (methylthio) tetrahydro-2H-pyran-3,4,5-triol;

Tshuaj& Lub Cev Muaj Zog:

Tsos: Hmoov

Kev Ntsuas: ≥99.0%

Ceev: 1.37 ± 0.1 g/cm3 (Kwv yees)

Kub Point: 607.9 ± 55.0 ℃ (Kwv yees)

PKa: 12.87 ± 0.70 (kwv yees)

Flash Point: 321.4 ± 31.5 ℃

Vapor Siab: 0.0 ± 1.8 mmHg ntawm 25 ℃

Index ntawm Refraction: 1.642

Sogliazin LX-4211 yog ob qho SGLT1/SGLT2 inhibitor nrog cov txheej txheem tshiab hypoglycemic. Cov kev tshawb fawb yav dhau los tau qhia nws qhov ua tau zoo hauv ob hom ntshav qab zib hom 1 thiab ntshav qab zib hom 2. Hauv peb qhov tseem ceeb ntawm ntau theem sib txawv Ⅲ kev sim sorglipin ua cov tshuaj insulin txuas ntxiv hauv 1Chemicalbook ntshav qab zib mellitus, pab pawg sorglipin tau ntsib qhov kawg yam tsis muaj kev mob ntshav qab zib hnyav lossis lwm yam SAEs thaum lub sijhawm kawm. Qhov no muab lub hauv paus kev kho mob rau kev pom zoo net ntawm Soglar raws li kev kho tshuaj insulin txuas ntxiv hauv kev kho mob ntshav qab zib hom 1. Soglijin LX-4211 yog cov tshuaj ntshav qab zib tshiab tsim los ntawm Sanofi thiab Lescon Pharmaceuticals. Raws li kev tiv thaiv ob leeg ntawm SGLT-1 thiab SGLT-2, cov tshuaj tuaj yeem txo qis cov ntshav qab zib tom qab noj mov, nce GLP-1 thiab txhawb kev tso cov piam thaj hauv cov zis.

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom lag luam nyob rau hauv patent tau muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm zaum kawg tshwj xeeb tshaj yog nrog tus neeg yuav khoom.

Cim npe nrov: lx-4211 cas 1018899-04-1, tuam ntxhab, cov chaw muag khoom, lub Hoobkas, yuav, hauv Tshuag

• Tug: H3B-6527 CAS 1702259-66-2
• Tom ntej: GLPG0187 CAS 1320346-97-1